Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Addex Therapeutics logo — Allosteric modulators for Human Health

Addex Therapeutics

Allosteric modulators for Human Health

Founded 2002 Switzerland Plan-les-ouates, Switzerland 19 employees Post Ipo Equity Total: $139.84M Biotechnology, Health Care +1

General Information

Company Name Addex Therapeutics
Founded Year 2002
Location Switzerland Plan-les-ouates, Switzerland +2
Founders / Decision Makers
Team member
Employees 19
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Post Ipo Equity
Social

Get notified when Addex Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Addex Therapeutics

Addex Therapeutics is a Swiss-based biotechnology company founded in 2002 and listed on the SIX Swiss Exchange and NASDAQ Capital Market under the ticker symbol "ADXN." The company focuses on the development and commercialization of allosteric modulators, a novel class of orally available small molecule drugs, for the treatment of neurological disorders. Their lead drug candidate, dipraglurant, a negative allosteric modulator for Parkinson’s disease levodopa induced dyskinesia (PD-LID), is positioned to begin a pivotal registration clinical trial in H1 2021. Furthermore, Addex is exploring dipraglurant's therapeutic potential in treating blepharospasm and other conditions. The company's collaboration with Janssen Pharmaceuticals, Inc. has led to the development of ADX71149, a positive allosteric modulator for the treatment of epilepsy. Addex has also licensed its GABAB PAM program to Indivior PLC for the treatment of addiction. Additionally, they have various preclinical programs targeting different neurological and psychiatric disorders. In their most recent funding round, the company secured a $2.10M post-IPO equity investment on 31 January 2024. With their innovative approach and diverse pipeline, Addex Therapeutics presents an intriguing opportunity for investors interested in the biotechnology and pharmaceutical sectors.

Taxonomy: Allosteric modulators, Neurological disorders, Pharmaceutical, Clinical-stage, Drug development, Parkinson's disease, Dyskinesia, Epilepsy, Addiction treatment, Preclinical programs, mGlu receptors, GABAB receptors, PTSD, Neurodegenerative disorders, NASDAQ

Funding Rounds & Investors (15)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 31 Jan 2024
Grant •••••• - 20 Sep 2023
Post-IPO Equity •••••• 1 •••• •••• 03 Aug 2023
Post-IPO Equity •••••• - 05 Apr 2023
Post-IPO Equity •••••• 1 •••• •••• 22 Jul 2022

View All 15 Funding Rounds

Addex Therapeutics Alternatives & Competitors

Addex Therapeutics vs
Gain Therapeutics
Gain Therapeutics United States

Unfolding the next generation of allosteric small molecule therapies to meet patient needs

IPO
26 employees
Biotechnology, Pharmaceutical
Compare Addex Therapeutics vs Gain Therapeutics

FAQ About Addex Therapeutics

Allosteric modulators for Human Health
Addex Therapeutics was founded in 2002.
Addex Therapeutics is headquartered in Plan-les-ouates, Switzerland.
Addex Therapeutics operates in the following industries: Biotechnology, Health Care, Pharmaceutical.
Addex Therapeutics has approximately 19 employees.
Addex Therapeutics has completed 15 funding rounds, raising a total of $139.84M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to Addex Therapeutics include Gain Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Addex Therapeutics and Gain Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Addex Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy